A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated coldrectal carcinoma

Cancer

Volumn 85, Issue 4, 1999, Pages 786-795

  Rothenberg, Mace L ^a,b,l   Cox, John V ^c   DeVore, Russell F ^d   Hainsworth, John D ^e   Pazdur, Richard ^f   Rivkin, Saul E ^g   Macdonald, John S ^h   Geyer Jr , Charles E ⁱ   Sandbach, John ^j   Wolf, Daniel L ^k   Mohrland, J Scott ^k   Elfring, Gary L ^k   Miller, Langdon L ^k   Von Hoff, Daniel D ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b CTRC Institute for Drug Development   (United States)

^c TEXAS ONCOLOGY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g SWEDISH MEDICAL CENTER   (United States)

^h TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^j Texas Cancer Center at Brackenridge   (United States)

^k PFIZER INC   (United States)

^l VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Clinical trial; Colorectal carcinoma; CPT 11; Irinotecan; Topoisomerase I

Indexed keywords

FLUOROURACIL; IRINOTECAN; LOPERAMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CARCINOMA; DIARRHEA; DOSE RESPONSE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DIARRHEA; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; VOMITING;

EID: 0033558004     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9     Document Type: Article

References (36)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Kosary CL, Gloeckler-Ries LA, Miller BA, Hankey BF, Harras A, Edwards BK, editors. SEER Cancer Statistics Review: 1973-1992. Bethesda (MD): National Cancer Institute; 1996 NIH Pub. No. 96-2789.
3. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
4. Moore TD, Cole KE, Christian MC, Arbuck SG. Trials of investigational drugs in colorectal cancer. In: Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, editors. Cancer of the colon, rectum and anus. New York: McGraw Hill, 1995:919-31.
5. Kono A, Hara Y. Conversion of CPT-11 into SN-38 in human tissues. Jpn J Cancer Chemother 1991;18:2175-8.
6. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-91.
7. Yoshida A, Ueda T, Wano Y, Nakamura T. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn J Cancer Res 1993;84:566-73.
8. Tanizawa A, Fujimori A, Fujimori Y, Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994;86:836-42.
9. Pommier Y, Tanizawa A, Kohn KW. Mechanisms of topoisomerase I inhibition by anticancer drugs. In: Liu LF, editor. Advances in pharmacology. New York: Academic Press, 1994:73-92.
10. Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol 1996;23(Supp 3):21-6.
11. Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997;8:837-55.
12. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993;11:909-13.
13. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M. Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 1993;11:2194-204.
14. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BR, Chen TL, et al. Phase I and pharmacokinetic study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 1994;54:427-36.
15. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
16. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15:251-60.
17. Ratain MJ, Mani S. Promising new agents in oncologic treatment. Curr Opin Oncol 1996;8:525-34.
18. Schaaf L, Ichhpurani N, Elfring G, et al. Influence of age on the pharmacokinetics of irinotecan and its metabolites, SN-38 and SN-38 glucuronide, in patients with previously treated colorectal cancer. Proc Am Soc Clin Oncol 1997;16: 202a.
19. 2 irinotecan (CPT-11) given every two weeks. Proc Am Soc Clin Oncol 1997;16:268a.
20. Abigerges D, Armand J-P, Chabot GG, Da Costa L, Fadel E, Cote C, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994;86:446-9.
21. Herait P, Fages B, Cote C, et al. Tumor response and stabilization rates are worthwhile surrogate efficacy endpoints in metastatic colorectal cancer (CRC). Analysis of data in 455 5-FU resistant patients treated with CPT-11. Proc Am Soc Clin Oncol 1997;16:288a.
22. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
23. Mayer RJ, Garnick MB, Steele GD Jr., Zamcheck N. Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer. Cancer 1978;42:1428-33.
24. Allen-Mersh TG, Kemeny N, Niedzwiecki D, Shurgot B, Daly JM. Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. Gut 1987;28:1625-9.
25. Shani A, O'Connell M, Moertel C, Schutt AJ, Silvers A, Go VL. Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma. Ann Intern Med 1978;88:627-30.
26. Ward U, Primrose JN, Finan PJ, Perren TJ, Selby P, Purves D, et al. The use of tumor markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal carcinoma. Br J Cancer 1993;67:1132-5.
27. Grem JL, Steinberg SM, Chen AP, et al. The utility of monitoring carcinoembryonic antigen (CEA) during systemic therapy for advanced colorectal cancer. Proc Am Soc Clin Oncol 1997;16:269a.
28. Gandia D, Abigerges D, Armand JP, Chabot G, Da Costa L, De Forni M, et al. CPT-11-induced cholinergic effects in cancer patients [letter]. J Clin Oncol 1993;11:196-7.
29. Von Hoff DD, Rothenberg ML, Pitot HC, et al. Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. Proc Am Soc Clin Oncol 1997;16:228a.
30. Fruehauf JP, Kyshtoobayeva A, Duarte T, et al. In vitro resistance of human colon cancer to 5-FU and CPT-11: correlations with treatment status and expression of thymidylate synthetase (TS) and MDR-1 P-glycoprotein (PGP). Proc Am Soc Clin Oncol 1997;16:295a.
31. Pilot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15:2910-19.
32. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer a Southwest Oncology Group Study. J Clin Oncol 1995;13:1303-11.
33. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
34. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12:2471-508.
35. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996;14:2959-67.
36. Buroker TR, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20.